From the Journals

Call it preclinical or subclinical, ILD in RA needs to be tracked


 

Screening and future research

While there is no evidence to recommend screening patients for ILD using CT, there are certain risk factors for ILD in RA patients, including a history of smoking, male sex, and high RA disease activity despite antirheumatic treatment, Dr. Volkmann said. In both of their practices, Dr. Davis and Dr. Volkmann screen with RA via HRCT and PFTs for ILD for patients with known risk factors that predispose them to the lung condition and/or for patients who report respiratory symptoms.

Dr. Joshua J. Solomon, a pulmonologist at National Jewish Health, Denver National Jewish Health

Dr. Joshua J. Solomon

“We still don’t have an algorithm [for screening patients], and that is a desperate need in this field,” added Joshua J. Solomon, MD, a pulmonologist at National Jewish Health, Denver, whose research focuses on RA-associated ILD. While recommendations state that all patients with scleroderma should be screened with CT, ILD incidence is lower among patients with RA, and thus these screening recommendations need to be narrowed, he said. But more research is needed to better fine tune recommendations, he said; “The only thing you can do is give some expert consensus until there are good data.”

Dr. Volkmann has received consulting and speaking fees from Boehringer Ingelheim and institutional support for performing studies on systemic sclerosis for Kadmon, Forbius, Boehringer Ingelheim, Horizon, and Prometheus. Dr. Gordon, Dr. Davis, and Dr. Solomon report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Ten-day methotrexate pause after COVID vaccine booster enhances immunity against Omicron variant
Federal Practitioner
How to prevent a feared complication after joint replacement
Federal Practitioner
Doctors urge screening for autoimmune disorders for patients with celiac disease
Federal Practitioner
Opioids increase risk for all-cause deaths in RA vs. NSAIDs
Federal Practitioner
Vaccination cuts long COVID risk for rheumatic disease patients
Federal Practitioner
Best estimates made for hydroxychloroquine retinopathy risk
Federal Practitioner
First Humira biosimilar launches in U.S.
Federal Practitioner
Prehospital COVID therapy effective in rheumatic disease patients
Federal Practitioner
New influx of Humira biosimilars may not drive immediate change
Federal Practitioner
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Federal Practitioner